This is an observational study designed to follow patients with RA who have had an
inadequate response to one or more anti-TNF therapies and who will receive Rituxan.
Approximately 1000 patients in the United States with RA who have had an inadequate response
to anti-TNF therapies and who will receive Rituxan therapy will be recruited. There is no
protocol mandated treatment assignment in this study. Patients will be evaluated and treated
according to their ... Read More
Spondyloarthropathies (SpA) are often diagnosed with a considerable delay (often 8-10 years
from symptom onset), because the available clinical, biochemical and radiological methods
are not sufficiently sensitive. TNF-a antagonists have recently been introduced for
treatment of SpA, and current data indicate a higher efficacy than previously available
therapies. The improved treatment options have increased the need for improved methods for
diagnosis, ... Read More
The objective of this study is to identify any problems and questions with respect to the
safety and efficacy of Xeljanz during the post-marketing period as required by the
regulation of MFDS.
The RISE Registry is an enhanced version of the ACR's Rheumatology Clinical Registry (RCR)
and allows for a simplified entry process, while establishing a best-in-class resource to
manage your patient population and improve patient care.
RISE provides participants with an infrastructure for robust quality improvement activities
leading to improved patient outcomes, patient population management and quality reporting
related to rheumatic diseases and drug ... Read More
The purpose of this study is demonstrate that subcutaneous abatacept is non-inferior (no
worse than) to subcutaneous adalimumab in the treatment of subjects with rheumatoid
arthritis who are biologic naive
The study investigates different criteria for remission based on MRI and circulating
biomarkers for inflammation, cartilage, connective tissue and bone turnover in patients with
axial spondyloarthritis treated with Golimumab. Furthermore, the study also investigates
factors that affect disease activity, function and participation by use of different
The purpose of this study is to examine the relationship between anti-drug antibodies, serum
drug concentrations, and clinical response for rheumatoid arthritis patients being treated
with etanercept, adalimumab or infliximab.
The purpose of this study is to determine whether switching to subcutaneous administration
of abatacept will be safe in participants with rheumatoid arthritis who previously received
long-term therapy with intravenous abatacept
Matrix metalloproteinases (MMPs) have been implicated in the cartilage degradation.
PG-530742 inhibits some MMPs, potentially limiting cartilage degradation and disease
progression. This study will test the efficacy and safety of PG-530742 in the treatment of
mild to moderate knee osteoarthritis.
The ACR Rheumatology Clinical Registry (RCR) is a tool developed to assist members in
practice improvement, local population management, and efficient, successful participation
in national quality programs. RCR integrates evidence-based quality measures aimed at
improving care and drug safety for patients with rheumatoid arthritis, osteoarthritis,
osteoporosis, gout and juvenile idiopathic arthritis.
The primary purpose of this study is to observe patients being treated with KRYSTEXXA in a
standard healthcare setting in order to evaluate the frequency and severity of infusion
reactions, anaphylaxis and immune complex related events. Additionally, serious adverse
events associated with KRYSTEXXA therapy will be identified.
The purpose of the study is to evaluate safety by collecting serious adverse events in
subjects with moderately to severely active rheumatoid arthritis who are unable to obtain
etanercept and who have failed one or more prior disease-modifying antirheumatic drugs
Source: Canadian Research & Education in Arthritis
Recruited patients will include those about to begin Disease-Modifying Antirheumatic Drug)
DMARD therapy or about to change DMARD therapy.
Disease activity will be monitored systematically every 3 months by the Disease Activity
Changes in standard DMARD and/or anti-Tumor Necrosis Factor α (anti-TNFα) therapy will be
made according to specific recommendations for patients receiving these therapies.
Biomarker samples will be collected every 3 ... Read More
Investigation of wholebody MRI and circulating biomarkers of inflammation, cartilage and
bone metabolism in patients with spondyloarthritis treated with adalimumab. Furthermore to
compare ultrasound examination with wholebody MRI etc.
This study will evaluate immune response following administration of zoster vaccine in
subjects with rheumatoid arthritis who are receiving background methotrexate and initiate 5
mg twice daily of tofacitinib or placebo for tofacitinib 2 to 3 weeks following vaccination.
The ultimate goal of treatment in early rheumatoid arthritis (RA) is remission, i.e. an
absence of signs and symptoms of the disease. However, the optimal way of reaching this goal
is not known.
Ultrasonography (US) is an imaging modality which application is rapidly growing. It has a
number of advantages over other advanced imaging techniques such as magnetic resonance
imaging (MRI), including low cost, good accessibility, and ability to scan many joints ... Read More